Cargando…
Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism
BACKGROUND: Oxaliplatin (Oxa) is the first-line chemotherapy drug for colorectal cancer (CRC), and Oxa resistance is crucial for treatment failure. Prostaglandin F(2α) synthase (PGF(2α)) (PGFS), an enzyme that catalyzes the production of PGF(2α), is involved in the proliferation and growth of a vari...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600807/ https://www.ncbi.nlm.nih.gov/pubmed/37900995 http://dx.doi.org/10.3748/wjg.v29.i39.5452 |
_version_ | 1785126066833063936 |
---|---|
author | Wang, Yi-Jun Xie, Xiao-Li Liu, Hong-Qun Tian, Hui Jiang, Xiao-Yu Zhang, Jiu-Na Chen, Sheng-Xiong Liu, Ting Wang, Shu-Ling Zhou, Xue Jin, Xiao-Xu Liu, Shi-Mao Jiang, Hui-Qing |
author_facet | Wang, Yi-Jun Xie, Xiao-Li Liu, Hong-Qun Tian, Hui Jiang, Xiao-Yu Zhang, Jiu-Na Chen, Sheng-Xiong Liu, Ting Wang, Shu-Ling Zhou, Xue Jin, Xiao-Xu Liu, Shi-Mao Jiang, Hui-Qing |
author_sort | Wang, Yi-Jun |
collection | PubMed |
description | BACKGROUND: Oxaliplatin (Oxa) is the first-line chemotherapy drug for colorectal cancer (CRC), and Oxa resistance is crucial for treatment failure. Prostaglandin F(2α) synthase (PGF(2α)) (PGFS), an enzyme that catalyzes the production of PGF(2α), is involved in the proliferation and growth of a variety of tumors. However, the role of PGFS in Oxa resistance in CRC remains unclear. AIM: To explore the role and related mechanisms of PGFS in mediating Oxa resistance in CRC. METHODS: The PGFS expression level was examined in 37 pairs of CRC tissues and paracancerous tissues at both the mRNA and protein levels. Overexpression or knockdown of PGFS was performed in CRC cell lines with acquired Oxa resistance (HCT116-OxR and HCT8-OxR) and their parental cell lines (HCT116 and HCT8) to assess its influence on cell proliferation, chemoresistance, apoptosis, and DNA damage. For determination of the underlying mechanisms, CRC cells were examined for platinum-DNA adducts and reactive oxygen species (ROS) levels in the presence of a PGFS inhibitor or its products. RESULTS: Both the protein and mRNA levels of PGFS were increased in the 37 examined CRC tissues compared to the adjacent normal tissues. Oxa induced PGFS expression in the parental HCT116 and HCT8 cells in a dose-dependent manner. Furthermore, overexpression of PGFS in parental CRC cells significantly attenuated Oxa-induced proliferative suppression, apoptosis, and DNA damage. In contrast, knockdown of PGFS in Oxa-resistant HCT116 and HCT8 cells (HCT116-OxR and HCT8-OxR) accentuated the effect of Oxa treatment in vitro and in vivo. The addition of the PGFS inhibitor indomethacin enhanced the cytotoxicity caused by Oxa. Treatment with the PGFS-catalyzed product PGF(2α) reversed the effect of PGFS knockdown on Oxa sensitivity. Interestingly, PGFS inhibited the formation of platinum-DNA adducts in a PGF(2α)-independent manner. PGF(2α) exerts its protective effect against DNA damage by reducing ROS levels. CONCLUSION: PGFS promotes resistance to Oxa in CRC via both PGF(2α)-dependent and PGF(2α)-independent mechanisms. |
format | Online Article Text |
id | pubmed-10600807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-106008072023-10-27 Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism Wang, Yi-Jun Xie, Xiao-Li Liu, Hong-Qun Tian, Hui Jiang, Xiao-Yu Zhang, Jiu-Na Chen, Sheng-Xiong Liu, Ting Wang, Shu-Ling Zhou, Xue Jin, Xiao-Xu Liu, Shi-Mao Jiang, Hui-Qing World J Gastroenterol Basic Study BACKGROUND: Oxaliplatin (Oxa) is the first-line chemotherapy drug for colorectal cancer (CRC), and Oxa resistance is crucial for treatment failure. Prostaglandin F(2α) synthase (PGF(2α)) (PGFS), an enzyme that catalyzes the production of PGF(2α), is involved in the proliferation and growth of a variety of tumors. However, the role of PGFS in Oxa resistance in CRC remains unclear. AIM: To explore the role and related mechanisms of PGFS in mediating Oxa resistance in CRC. METHODS: The PGFS expression level was examined in 37 pairs of CRC tissues and paracancerous tissues at both the mRNA and protein levels. Overexpression or knockdown of PGFS was performed in CRC cell lines with acquired Oxa resistance (HCT116-OxR and HCT8-OxR) and their parental cell lines (HCT116 and HCT8) to assess its influence on cell proliferation, chemoresistance, apoptosis, and DNA damage. For determination of the underlying mechanisms, CRC cells were examined for platinum-DNA adducts and reactive oxygen species (ROS) levels in the presence of a PGFS inhibitor or its products. RESULTS: Both the protein and mRNA levels of PGFS were increased in the 37 examined CRC tissues compared to the adjacent normal tissues. Oxa induced PGFS expression in the parental HCT116 and HCT8 cells in a dose-dependent manner. Furthermore, overexpression of PGFS in parental CRC cells significantly attenuated Oxa-induced proliferative suppression, apoptosis, and DNA damage. In contrast, knockdown of PGFS in Oxa-resistant HCT116 and HCT8 cells (HCT116-OxR and HCT8-OxR) accentuated the effect of Oxa treatment in vitro and in vivo. The addition of the PGFS inhibitor indomethacin enhanced the cytotoxicity caused by Oxa. Treatment with the PGFS-catalyzed product PGF(2α) reversed the effect of PGFS knockdown on Oxa sensitivity. Interestingly, PGFS inhibited the formation of platinum-DNA adducts in a PGF(2α)-independent manner. PGF(2α) exerts its protective effect against DNA damage by reducing ROS levels. CONCLUSION: PGFS promotes resistance to Oxa in CRC via both PGF(2α)-dependent and PGF(2α)-independent mechanisms. Baishideng Publishing Group Inc 2023-10-21 2023-10-21 /pmc/articles/PMC10600807/ /pubmed/37900995 http://dx.doi.org/10.3748/wjg.v29.i39.5452 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Wang, Yi-Jun Xie, Xiao-Li Liu, Hong-Qun Tian, Hui Jiang, Xiao-Yu Zhang, Jiu-Na Chen, Sheng-Xiong Liu, Ting Wang, Shu-Ling Zhou, Xue Jin, Xiao-Xu Liu, Shi-Mao Jiang, Hui-Qing Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title | Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title_full | Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title_fullStr | Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title_full_unstemmed | Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title_short | Prostaglandin F(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F(2α)-dependent and F(2α)-independent mechanism |
title_sort | prostaglandin f(2α) synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin f(2α)-dependent and f(2α)-independent mechanism |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600807/ https://www.ncbi.nlm.nih.gov/pubmed/37900995 http://dx.doi.org/10.3748/wjg.v29.i39.5452 |
work_keys_str_mv | AT wangyijun prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT xiexiaoli prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT liuhongqun prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT tianhui prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT jiangxiaoyu prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT zhangjiuna prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT chenshengxiong prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT liuting prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT wangshuling prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT zhouxue prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT jinxiaoxu prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT liushimao prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism AT jianghuiqing prostaglandinf2asynthasepromotesoxaliplatinresistanceincolorectalcancerthroughprostaglandinf2adependentandf2aindependentmechanism |